ClinicalTrials.gg
CompletedNCT07550751FESSUpdated Apr 24, 2026

Optimal Dosage of Melatonin for Preoperative Sedation in FESS

A Phase 4 interventional study of Melatonin in Clinical Trial, sponsored by Aswan University Hospital. Completed at 1 site in Egypt. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-24.

Sponsored by Aswan University Hospital · Phase 4, Interventional, and Other

From the registry’s dates

  • Registered 1 year 8 months after the study started (first participant enrolled Aug 2024, registered Apr 2026).
Phase
Phase 4
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

To determine the optimal dosage of Melatonin for preoperative sedation in patients undergoing FESS.

02

Conditions studied

  • Clinical Trial
03

In context

Lead sponsor

Aswan University Hospital is the lead sponsor of 97 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- ASA 1 ASA 2 patients scheduled for elective FESS under general anesthesia

Exclusion criteria

Exclusion Criteria:

  • or to the drug
  • Severe psychiatric disorders.
  • Regular use of sedatives or analgesics.
  • Pregnancy or breastfeeding
  • Significant systemic diseases such as severe cardiovascular, hepatic, or renal dysfunction.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Care provider)
Enrollment
160 participants (actual)

Study arms

  • Other
    A

    placebo

    Drug: Melatonin

  • Other
    B

    Melatonin 3mg

    Drug: Melatonin

  • Other
    C

    Melatonin 5mg

    Drug: Melatonin

  • Other
    D

    Melatonin 10mg

    Drug: Melatonin

Interventions

  • comparison between placebo and different melatonin doses(3-5-10 mg)

06

What researchers measure

Primary outcomes

  1. preoperative sedation using ramsay sedation scale

    assess of sedation pre-induction of anesthesia and one hour after recovery

    Time frame: just before intravenous anesthetic induction and one hour after recovery

Secondary outcomes

  1. perioperative anxiety using The six-item State-Trait Anxiety Inventory (STAI-6) scale

    Questionnaire assessment of anxiety

    Time frame: Baseline one hour before surgery, just before induction of anaesthesia and one hour after recovery

  2. Measuring heart rate in beat/min

    Effect of preoperative different doses of melatonin on heart rate as a part of hemodynamic stability

    Time frame: Baseline and perioperative

  3. Measuring blood pressure (systolic, diastolic and mean arterial pressure) in mmHg

    Effect of preoperative different doses of melatonin on blood pressure as a part of hemodynamic stability

    Time frame: Baseline and perioperative

  4. Measuring oxygen saturation (in percentage) using pulse oximeter

    Effect of preoperative different doses of melatonin on oxygen saturation as a part of hemodynamic stability

    Time frame: Baseline and perioperative

  5. Postoperative pain assessment using Visual Analogue score of pain

    Assessment of the effect of melatonin on postoperative pain management

    Time frame: 1,2,4and6 hours postoperative

07

Study locations

1 site
  • Aswan university hospitals
    Aswān, Egypt
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2024 to primary completion in Apr 2025, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2026
First posted
Apr 24, 2026
StartActual
Aug 1, 2024
Primary completionActual
Apr 30, 2025
CompletionActual
Oct 1, 2025
Last update
Apr 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07550751
Lead sponsor
Aswan University Hospital
Responsible party
Osaid Abdelshakour Elsayed Abdallah (anesthesia, surgical intensive care unit and pain management resident doctor., Aswan University Hospital) — Principal investigator
First posted
Apr 24, 2026
Start date
Aug 1, 2024
Primary completion
Apr 30, 2025
Completion
Oct 1, 2025
Last update
Apr 24, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Melatonin

Start the discussion